Novel Agents Fill the Pipeline for Pancreatic Cancer
From chemotherapeutic agents to novel biologicals, there are promising treatment options on the horizon.
From chemotherapeutic agents to novel biologicals, there are promising treatment options on the horizon.
Adding algenpantucel-L immunotherapy to standard adjuvant treatment may improve survival in patients undergoing R0/R1 resection for pancreatic cancer.
The pancreatic protein, PEAK1, is a novel biomarker and new therapeutic target in pancreatic ductal adenocarcinoma (PDAC).
In vivo imaging is a non-invasive diagnostic approach to successfully localize small insulinomas.
Classifications for pancreatic neuroendocrine tumors are prognostic for recurrence-free survival and can be adopted in clinical practice.
Increased risk seen with frequent bitewings in old machines and panorex films in young children.
Researchers aimed to develop screening methods to detect curable, noninvasive pancreatic neoplasms.
Metformin use was associated with improved outcome of patients with diabetes and pancreatic cancer, according to a study published in Clinical Cancer Research online.
Percutaneous irreversible electroporation (IRE) is feasible and safe in patients with locally advanced pancreatic adenocarcinoma, with 2 of 8 patients with unresectable disease achieving a margin-negative resection.
The efficacy of gemcitabine in treating pancreatic cancer can be greatly improved by a second drug that increases gemcitabine levels by preventing its breakdown, according to a study published online February 28 in Cancer Discovery.